PHYLLIS SCARCE: Open Payments
NPI 1316996986 · DANVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,904 in 201 payments from 21 companies in 2025. Trend: 2023 $3,766 · 2024 $4,086 · 2025 $3,904
Food & beverage: $3,523Education: $381
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 26 | $655 |
| ABBVIE INC. | 34 | $630 |
| UCB, Inc. | 18 | $521 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 22 | $408 |
| Regeneron Healthcare Solutions, Inc. | 14 | $253 |
| Novartis Pharmaceuticals Corporation | 11 | $246 |
| GENZYME CORPORATION | 12 | $240 |
| Galderma Laboratories, L.P. | 22 | $180 |
| LEO Pharma Inc. | 12 | $148 |
| Lilly USA, LLC | 10 | $138 |
Products named: TREMFYA, DUPIXENT, Bimzelx, RINVOQ, SKYRIZI, ILUMYA, NEMLUVIO, COSENTYX.
Industry payments across VA — which companies pay providers there.
